This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Woodhouse, K.W. Articles by Rawlins, M.D. Search for Related Content PubMed Articles by Woodhouse, K.W. Articles by Rawlins, M.D. Social Bookmarking                         What's this?

N-Acetylation Phenotype in Bladder Cancer

Wolfson Unit of Clinical Pharmacology, The University, Newcastle upon Tyne

P.C. Adams

Wolfson Unit of Clinical Pharmacology, The University, Newcastle upon Tyne

A. Clothier

Wolfson Unit of Clinical Pharmacology, The University, Newcastle upon Tyne

J.C. Mucklow

Department of Clinical Pharmacology, City General Hospital, Stoke-on-Trent

M.D. Rawlins

Wolfson Unit of Clinical Pharmacology, The University, Newcastle upon Tyne

1 N-acetylation phenotype has been examined in 30 patients with bladder cancer and in 27 controls of similar age.

2 59% of controls and 70% of bladder cancer patients were phenotypically 'slow' acetylators. This difference was not significant (P>0.30).

3 Within phenotypes, isoniazed half life was similar in controls and bladder cancer patients.

4 N-acetylation phenotype is unlikely to be a major determinant in the pathogenesis of bladder cancer in the population studied.

Human & Experimental Toxicology, Vol. 1, No. 4, 443-445 (1982)
DOI: 10.1177/096032718200100411


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?